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Abstract
Background: CC-chemokine receptor 7 (CCR7), which plays an important role in cell directional movement, is
highly expressed in various cancers and positively related to lymph node metastasis. The inflammatory cytokine
tumour necrosis factor (TNF)-α promotes tumour progression and lymph node metastasis in gallbladder cancer
(GBC). However, the expression of CCR7 in GBC is unclear, and its role in the TNF-α-induced lymphatic metastasis
of GBC requires further research.
Methods: The expression of CCR7 in clinical samples was detected by immunohistochemistry, and the relationship
between CCR7 and clinicopathological factors or the TNF-α level of the bile was analyzed. After treatment with
various concentrations of TNF-α, CCR7 expression in GBC cell lines was measured by Western blotting. The relative
luciferase reporter assay, site-directed mutagenesis and chromatin immunoprecipitation were used to analyze the
promoter activity and transcriptional regulation of CCR7. MAPKs inhibitors were used to explore the upstream
signalling molecules of AP-1. We established a NOZ cell line stably expressing lentiviral CCR7 shRNA that effectively
silenced the expression of CCR7, and to determine the role of TNF-α - CCR7 axis in the migration of GBC cells to
the lymphatic system by transwell assays and animal experiments.
Results: CCR7 was highly expressed in GBC samples. Higher expression of CCR7 was associated with American
Joint Committee on Cancer (AJCC) staging and lymph node metastasis. Moreover, we found that CCR7 expression
in GBC tissue was positively correlated with the levels of TNF-α in the bile, and that TNF-α enhanced the promoter
activity and protein expression of CCR7 through the “ERK1/2-AP-1” and “JNK-AP-1” pathways. Finally, we revealed
that TNF-α could promote GBC cell migration to lymphatic endothelial cells or lymph nodes through upregulation
of CCR7 in vitro and in vivo.
Conclusions: Our study suggests that CCR7 is highly expressed in GBC, and mediates the TNF-α-induced lymphatic
metastasis of GBC through the “TNF-α - ERK1/2 - AP-1 - CCR7” and “TNF-α - JNK - AP-1 - CCR7” pathways.
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Background
Gallbladder cancer (GBC) is a rare and highly lethal dis-
ease. It accounts for 80-95 % of biliary tract malignan-
cies, representing the most common cancer of the
biliary tree [1]. GBC is a highly malignant tumour and
has an extremely poor prognosis [2]. It tends to
metastasize to the lymph nodes in its early stages, which
seriously affects the prognosis. Chronic inflammation in-
duced by gallstones is a major risk factor for GBC ac-
cording to epidemiological investigations [1, 3].
The hypothesis that inflammation causes cancer dates
back to the 19th century [4]. Follow-up studies indicate
that inflammation can also promote tumour progression
[5, 6]. Cytokines, such as tumour necrosis factor alpha
(TNF-α), secreted by inflammatory cells play important
roles in cancer-related inflammation [7]. In our previous
study, we demonstrated that TNF-α can promote lym-
phangiogenesis and lymph node metastasis of GBC [8].
However, the specific mechanism explaining how GBC
cells migrate to the lymphatic vessels remains to be elu-
cidated. Whether TNF-α can promote this migration
also requires further study.
Chemokines, a group of small molecule proteins (8–11
kd) secreted by endothelial cells, fibroblasts and macro-
phages, are another important cytokine in cancer-related
inflammation. Chemokine receptors, which combine
with the corresponding chemokines, are G-protein-
coupled receptors, including CXC, CC, CX3C and XC
receptors [9, 10]. Previous studies demonstrated that
chemokine receptors and ligands play important roles in
the directional movement of many cell types, such as
inflammatory cell recruitment [11] and lymphocyte
homing [12]. In 2001, Anja Muller first proposed that
the process of tumour cell migration to target organs,
including lymphatic vessels and lymph nodes, may be
similar to that of lymphocyte homing, and suggested
that chemokines and their receptors (CXCR4, CCR7 and
CCR10) have a critical role in determining the metastatic
destination of tumour cells [13]. Subsequently, many
studies have confirmed this conclusion.
Chemokine receptors are primarily expressed on the
membrane of cancer cells and mediate cancer cell mi-
gration to target organs by combination with their corre-
sponding ligands. CC-chemokine receptor 7 (CCR7) is
the specific receptor for chemokines CCL21/CCL19. It
was demonstrated that CCR7 is associated with lymph
node metastases of the malignancies [9, 10]. Research in
various types of tumours, such as cervical cancer [14],
oesophageal squamous cell carcinoma [15], gastric can-
cer [16], and melanoma [17], have confirmed that the
CCR7-CCL21/CCL19 axis is involved in lymphatic me-
tastases. However, the expression of CCR7 in GBC and
its relationship with lymph node metastasis of GBC is
unknown. Therefore, we hypothesized that TNF-α might
promote lymphatic metastasis of gallbladder cancer via
upregulation of CCR7.
In this study, we detected the expression of CCR7 in
gallbladder cancer for the first time, and revealed the re-
lationship between CCR7 and the clinicopathological
factors of GBC patients. We found that CCR7 expres-
sion in GBC tissue is positively correlated with the levels
of TNF-α in the bile, and further determined that TNF-
α enhances the promoter activity and protein expression
of the CCR7 gene through the “ERK1/2-AP-1 and JNK-
AP-1” pathways. Moreover, we indicated that TNF-α
could promote GBC cell migration to LECs in vitro and
promote lymph node metastasis in the orthotopic trans-
plantation of GBC through the upregulation of CCR7.
Methods
Specimens and immunohistochemistry
The study with clinical samples was approved by the
Ethics Committee of the Medical Faculty of Fujian Med-
ical University in China. Forty-two paraffin-embedded
gallbladder cancer tissues and 22 para-carcinoma tissues
were randomly obtained from the archives of the De-
partment of Pathology at Fujian Medical University
Union Hospital (from 2006 to 2013). Written informed
consent was obtained from all patients before surgery.
All patients included in this study had not been given
any preoperative chemotherapy or other therapy such as
radiotherapy. Immunohistochemistry analysis was per-
formed as described previously [18]. Ten different fields
were selected randomly from each slice and the percent-
age of positive cells was counted using a bright field light
microscope (400×). The degree of immunostaining was
reviewed and scored independently by two pathologists
based on the intensity of staining: 0 (no staining), 1
(weak staining, light yellow), 2 (moderate staining, yel-
low brown), and 3 (strong staining, brown). The number
of positive cells was graded as: 0 (<10 %), 1 (11–25 %), 2
(26–50 %), 3 (51–75 %) and 4 (>75 %). The two grades
were multiplied together and the staining of each
sample was evaluated as follows: negative, <1 points
(-); positive, >1 point: 1 to 4 points (+), 5 to 8 points
(++); 9 to 12 points (+++ ~ ++++).
Cell culture and transfection
The human gallbladder cancer cell lines: NOZ (obtained
from the Health Science Research Resources Bank in
Japan), GBC-SD (purchased from the Shanghai Institutes
for Biological Sciences in China) and SGC-996 (provided
by the Tumour Cytology Research Unit, Medical College,
Tongji University, Shanghai, China) were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco,
USA) containing 10 % foetal bovine serum (FBS,
Hyclone, USA). Human dermal lymphatic endothelial
cells (HDLECs, purchased from Sciencell, USA) were
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incubated in endothelial cell medium (Sciencell). Cell
transfection was carried out in 6-well plates at a
density of 5 × 105 cells/well or 24-well plates at a
density of 1 × 105 cells/well by using Lipofectamine
2000 (Invitrogen, USA) according to the manufac-
turer’s instructions. All of the cells were incubated at
37 °C in a humid atmosphere of 95 % air and 5 %
CO2.
Western blotting
Western blotting analysis was performed as described
previously [19]. Monoclonal rabbit anti-human CCR7
antibody (1:2000), rabbit anti-human c-Jun (AP-1, 1:1000),
rabbit anti-human p-c-Jun (p-AP-1, 1:1000), rabbit anti-
human ERK1/2 (1:1000), rabbit anti-human p-ERK1/2
(1:500), rabbit anti-human JNK (1:1000), rabbit anti-
human p-JNK (1:1000), rabbit anti-human p38MAPK
(1:1000), and rabbit anti-human p-p38MAPK (1:1000)
were purchased from Abcam. Monoclonal mouse anti-
human β-actin (1:1000) was obtained from Santa Cruz.
The signals were detected with an ECL kit (Beyotime,
China) by following the manufacturer’s instructions.
Real-time polymerase chain reaction
Real-time polymerase chain reaction (RT-PCR) was used
to clone the CCR7 promoter fragment used in the site-
directed mutagenesis and ChIP assay. Total RNA was
isolated from the cultued cells using TRIzol reagent
(Invitrogen) according to the manufacturer’s instruc-
tions. Total RNA was reverse transcribed using the Re-
vert Aid First Strand cDNA Synthesis Kit (Thermo,
USA) following the manufacturer’s instructions. These
cDNA were used as the template for PCR amplification.
The primers are shown in Table 1. The PCR conditions
were as follows: 95 °C for 5 min, 95 °C for 30 s, and 61 °C
for 30 s for 32 cycles.
Construction of CCR7 promoter luciferase reporter
plasmids and dual-luciferase reporter assay
Primers (Table 1) containing an XhoI or BglII (Thermo)
restriction site were used to amplify a series of 5′-dele-
tion CCR7 gene promoter fragments that were con-
nected to the plasmid PGL4.10-Basic vector (Promega,
USA) carrying a firefly luciferase reporter gene. These
recombinants were named PGL4-1055 (−1055 to +74 nt,
relative to the transcription start site “ATG”), PGL4-725
(−725 to +74 nt), PGL4-462 (−462 to +74 nt), PGL4-243
(−243 to +74 nt) and PGL4-108 (−108 to +74 nt). Forty-
eight hours after transfection with promoter vector, cells
were lysed and the intracellular luciferase activity of the
lysates was measured using the Dual-Luciferase Reporter
Assay System (Promega) according to the manufacturer’s
instructions. The relative luciferase units were obtained
by comparison to the luciferase activity of the pRL-TK
plasmid (plasmid carrying a renilla luciferase report gene
as an internal reference). Luminescence measurement
was carried out on a luminometer (Orion II Microplate
Luminometer, Berthold Detection Systems, Germany).
Identification of putative transcription factor binding sites
The web sites TFbind (http://tfbind.hgc.jp/) and Promoter
Scan (http://www-bimas.cit.nih.gov/molbio/proscan/) were
used to search for potential transcription factor binding
sites.
Table 1 The primer sequences used in this study
Oligonucleotides Sequences (5′→ 3′)a Length of products (bp)
CCR7 promoter cloning
−1055/+74F ccg CTCGAG CAGCCCAAACATCCAACT 1129
−725/+74F ccg CTCGAG GTGATGGTTGCATAACTCTG 799
−462/+74F ccg CTCGAG GGAAAGCCATTTGGGACT 536
−243/+74F ccg CTCGAG GGATCCTATGACCAGCGAC 317
−108/+74F ccg CTCGAG TGGCTTCTCCGACAACTT 182







AP1 ChIP-F CACCTTTCTTCTGCCCCTTTATC 134
AP1 ChIP-R TCAAGCCCCTTTTAAGTTGTCGG
aLowercase letters represent the protective-bases; italic letters represent the restriction enzyme cutting site; underlined letters represent the bases of mutation
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Site-directed mutagenesis
Site-directed mutagenesis was performed by overlap ex-
tension PCR as previously described [20]. The primers
targeting the two mutation sites of the AP-1 binding
sites are shown in Table 1.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed according to the manu-
facturer’s instructions using the EZ-Magna ChIP kit
(Merck Millipore, Germany). An antibody against AP-1
(c-Jun, phosphor S63, Abcam, England) and negative
control normal rabbit IgG were used for immunoprecip-
itation. The primers for PCR are shown in Table 1.
AP-1 (c-Jun) siRNA oligonucleotide treatment of cells
The AP-1 (c-Jun) siRNA interference sequence has been
described previously [21] (named siAP-1). It and the
non-targeting control (named siNC) were synthesized
chemically by GenePharma Co., Ltd. (Suzhou, China).
The transient transfection was performed according to
the manufacturer’s instructions.
Construction of a stable NOZ cell line with lentiviral CCR7
shRNA
We designed three siRNA sequences targeting the CCR7
gene (si1, si2, si3) and identified one of them, si3 (5′-
GCGUCCUUCUCAUCAGCAA-3′), to effectively knock
down CCR7 expression in NOZ cells. We used this se-
quence to construct a lentiviral vector expressing a
CCR7 shRNA (named LV-shCCR7) and employed a
non-targeting sequence lentiviral vector as control
(named LV-shNC). Both vectors were constructed by
GenePharma Co., Ltd. (Suzhou, China). The lentiviral
vectors were used to infect NOZ cells with puromycin
treatment for 2 weeks to screen for stably infected cells.
Transwell assay
Cell migration and invasion were assayed using trans-
wells (24-well format) with 8 μm polycarbonate mem-
branes (Millipore, USA). The upper side of the
membrane was covered with matrigel matrix (diluted
1:7) (BD Biosciences, USA) and air-dried for 1 h of incu-
bation at 37 °C. The lower side of the membrane was
covered with 5 μg fibronectin (BD Biosciences). Cells
were resuspended in endothelial cell medium (ECM)
after 8 h of serum-free starvation. Then, 200 ul ECM
medium with 1 × 104 NOZ cells was seeded to the upper
chamber 500 ul ECM medium with or without 2 × 104
HDLECs was added to the bottom chamber as attrac-
tants. After incubation for 48 h, the cells on the upper
surface of the membrane were removed and the cells at
the bottom of the filter were fixed with a stationary li-
quid of 95 % ethanol and 5 % acetic acid for 30 min and
then stained with haematoxylin and eosin (H&E). The
number of cells in each chamber was counted in nine
random different fields (400×) using a bright field light
microscope. Each experiment was repeated in triplicate.
Animal experiments
Male 6-week old BALB/c nude mice were purchased
from Shanghai SLAC Laboratory Animals Co. (Shanghai,
China). All operations were according to institutional
guidelines and were approved by the Ethics Committee
of the Medical Faculty of Fujian Medical University. The
orthotopic xenograft models were established following
the method by Qiang Du [22]. Forty-eight mice were
randomly divided into two groups (NOZ group and LV-
shCCR7 group). Two weeks after inoculation, these two
groups were each randomly divided into two group
(twelve mice/group), and exogenous TNF-α (2 μg⁄kg)
was injected into the peritoneal cavity of the two groups
(one of the NOZ group and one of the LV-shCCR7
group) three times a week. The others (control group)
were injected with normal saline. Five weeks after cell
injection, the mice were euthanized by exposure to CO2,
and the primary tumours were dissected and excised.
Statistics
The results are presented as the mean ± SD from at least
three independent experiments. Data analyses were per-
formed with SPSS software (SPSS 13.0) by the analysis
chi-square test (χ2 test), Fisher exact probability test,
variance (ANOVA) and t-test. A two-sided P-value <
0.05 was considered statistically significant.
Results
1. The expression of CCR7 in human gallbladder
cancer and the relationship between CCR7 and
clinicopathological factors.
We analyzed the expression of CCR7 in 42 clinical
samples from gallbladder cancer patients and 22
normal gallbladder tissues adjacent to the carcinoma
using immunohistochemistry. CCR7 was detected
in the cytoplasm and membrane of GBC cells
(Fig. 1b–d). However, negative or low levels of
CCR7 expression were observed in the adjacent
tissues. As shown in Table 2, CCR7 was expressed in
90.47 % (38/42) of GBC samples, which was
significantly higher than that of adjacent tissues
(22.73 %) (P < 0.05).
The relationship between CCR7 expression and
select clinicopathologic factors is shown in Table 3.
Higher expression (+++ to ++++, strong staining) of
CCR7 was associated with AJCC staging (I-IIa vs
IIb-IV, P = 0.008 < 0.05) and lymph node metastasis
(negative vs positive, P = 0.003 < 0.05), but not with
age, gender, histological grade, and classification.
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Taken together, CCR7 overexpression may be
involved in the lymph node metastasis of gallbladder
cancer.
2. CCR7 expression in GBC tissue is positively
correlated with the levels of TNF-α in the bile.
Our previous study demonstrated that the level of
TNF-α in the bile of GBC patients was significantly
higher than that in patients with cholesterol
gallbladder polyps [8]. To analyze the relationship
between CCR7 expression and TNF-α levels in
the bile, we detected the expression of CCR7 by
immunohistochemistry in 20 specimens from the
patients whose TNF-α levels in the bile had been
detected by ELISA in our previous study [8]. As
shown in Table 4, the level of TNF-α in the bile of
GBC patients with strong staining of CCR7 was
significantly higher than that of patients with
negative/week/moderate staining (P < 0.05).
3. TNF-α promotes the expression of CCR7 in
gallbladder cancer cell lines.
To explore whether TNF-α could promote the
expression of CCR7, we first detected the protein
levels of CCR7 in three GBC cell lines (NOZ, GBC-
SD, and SGC-996), and measured the expression of
CCR7 again in these cell lines after treatment with
exogenous TNF-α. The expression of CCR7 protein
in all three cell lines was confirmed. The levels of
CCR7 protein in NOZ and SGC-996 cells were
higher when compared to the GBC-SD cell lines
(Fig. 2a, d). Thus, we employed the NOZ and SGC-
996 cell lines in the next step of detection. GBC cells
Fig. 1 Representative IHC staining examples for CCR7 expression in gallbladder tissues (400×). a Negative, b weak, c moderate, d strong






GBC 42 38 4 90.47*
Adjacent-tissue 22 5 17 22.73
*P < 0.05
Table 3 The relationship between CCR7 and the
clinicopathological factors of GBC
Factors case
number
CCR7 χ2 P value
- ~ ++ +++ ~ ++++
Age(year) 0.475 0.491
<60 20 7 13
≥60 22 10 12
Gender 2.888 0.089
Male 19 5 14
Female 23 12 11
AJCC staging 6.959 0.008
I-IIa 17 11 6
IIb-IV 25 6 19
Histological grade 1.037 0.595
Poor 14 7 7
Moderate 15 6 9
High 13 4 9
Classification 1.993 0.158
Adenocarcinoma 36 13 23
Others 6 4 2
Lymph node metastasis 8.968 0.003
Positive 24 5 19
Negative 18 12 6
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were incubated in 6-well plates and treated with
various doses of TNF-α (5, 10, 20, and 50 ng⁄mL) for
12 h; the control groups were not treated with TNF-
α. The expression of CCR7 was detected by Western
blotting. As shown in Fig. 2b, e, TNF-α promoted
the expression of CCR7 in NOZ and SGC-996 cell
lines in a dose-dependent manner, and the peak
effect appeared after treatment with 50 ng⁄mL
(NOZ) and 20 ng/mL (SGC-996) TNF-α.
Subsequently, we detected the CCR7 protein in
NOZ and SGC-996 cells after treatment with 20 ng/
mL TNF-α for 6, 12, and 24 h. The peak effect
appeared after the 12-hour treatment with TNF-α
(Fig. 2c, f ). The NOZ cell line had the highest level
of CCR7, so we used NOZ cells for further study.
4. TNF-α enhanced the promoter activity and protein
expression of CCR7 through the “ERK1/2-AP-1 and
JNK-AP-1” pathways.
To further explore the mechanism by which TNF-α
upregulates CCR7, we first analyzed the promoter
activity of CCR7 and determined the putative
transcription factors binding to the promoter. A
series of 5′-deletion constructs of the CCR7 promoter
were transiently transfected into NOZ cells. As shown
in Fig. 3a, the cells exhibited similar luciferase activities
when transfected with either PGL4-1055/+74,
PGL4-725/+74, PGL4-462/+74 or PGL4-243/+74,
while luciferase activity markedly declined when
transfected with PGL4-108/+74, suggesting that
the region of -243 nt to -108 nt is crucial for the
full activity of the CCR7 promoter. Two potential
AP-1 binding sites were found (Fig. 3b) in the
−243 nt to −108 nt region of the promoter by
using the TFbind and Promoter Scan programs.
The site-directed mutagenesis assay indicated that
the AP-1(2)-binding site, but not the AP-1(1)-
binding site, is crucial for the full activity of the
CCR7 promoter (Fig. 3c). The ChIP assay was
performed to confirm that the AP-1 transcription
factor binds to the CCR7 promoter in vivo.
To determine the effect of the TNF-α⁄AP-1 signalling
pathway on the promoter activity and protein
expression of the CCR7 gene, we measured the
luciferase intensity of the PGL4-462/+74 plasmid
and CCR7 expression in NOZ cells treated with
TNF-α or transfected with AP-1 (c-Jun) siRNA
against AP-1 (siAP-1). As shown in Fig. 3e, f, g, the
promoter activity and protein levels of the CCR7
gene were significantly reduced after transfection
with siAP-1. TNF-α enhanced the expression of
CCR7 and increased the luciferase activity of the
CCR7 promoter. In contrast, when NOZ cells were
transfected with siAP-1, the ability of TNF-α to
upregulate luciferase activity and the protein
expression of CCR7 were blunted.
To determine which members of the MAPKs family
(ERK1/2, JNK or p38MAPK) are involved in the
upregulation of CCR7 induced by TNF-α, Western
blotting was used to detect the expression of ERK1/
Table 4 The relationship between TNF-α levels in the bile and
the expression of CCR7 in the tissues of GBC patients
CCR7 staining case number TNF-α(pg/ml) P value
- ~ ++ 4 416.6 ± 54.14 0.022
+++ ~ ++++ 16 657.1 ± 45.49
Fig. 2 The expression of CCR7 in different GBC cell lines after treatment with TNF-α. a, d Expression of CCR7 in three human GBC cell lines (NOZ,
GBC-SD, and SGC-996) detected by Western blotting. The levels of CCR7 protein in NOZ and SGC-996 cells were higher when compared to the
GBC-SD cell lines. b, e GBC cells (NOZ and SGC-996) were treated with varying concentrations of TNF-α (5, 10, 20 and 50 ng⁄mL) for 12 h. The
CCR7 protein level was measured by Western-blotting; the level increased in a dose-dependent manner. c, f CCR7 protein in NOZ and SGC-996
cells was detected after treatment with 20 ng/mL TNF-α for 6, 12, and 24 h. (*P < 0.05)
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2, p-ERK1/2, JNK, p-JNK, p38MAPK and p-p38MAPK
in NOZ cells with or without treatment with TNF-α.
The expression of p-ERK1/2, p-JNK and p-p38MAPK
was increased (Fig. 3h). Thus, we assessed the effects of
MAPK pathway inhibitors on the luciferase activity of
the CCR7 promoter and the protein expression of
AP-1, p-AP-1 and CCR7. As shown in Fig. 3i, j, k,
treatment of NOZ cells with PD98059 (50 μM),
Fig. 3 TNF-α enhanced the promoter activity and protein expression of the CCR7 gene through the “ERK1/2-AP-1 and JNK-AP-1” pathways. a
Activity analysis of the CCR7 promoter. NOZ cells were transfected with 1 μg each of the CCR7 promoter constructs and 0.1 μg of pRL-TK. Each
transfection was performed in duplicate. b Nucleotide sequence of the −243 to −108 region of the CCR7 promoter. The two putative AP-1
binding sites (CTCTGTCACC and ATGAGTCAG) were marked with red letters (named AP-1(1) and AP-1(2)). c Site-directed mutagenesis assay. The
mutated construct PGL4-AP1mut2 but not PGL4-AP1mut1 exhibited lower activities than the non-mutated construct PGL4-462/+74. d ChIP assay.
Chromatin from NOZ cells was immunoprecipitated with the anti-AP-1 antibody. The total extracted DNA (Input) and the immunoprecipitated
samples were PCR-amplified using primers specific to the regions of the CCR7 promoter containing the AP-1(2) binding site (134 bp). A normal
rabbit IgG and no antibody sample were also included as controls. e–g The effect of the TNF-α⁄AP-1 signalling pathway on the promoter activity
and protein expression of the CCR7 gene. After transfection with AP-1 siRNA, the promoter activity and protein level of CCR7 were accordingly
reduced, irrespective of treatment with TNF-α. h The expression of p-ERK1/2, p-JNK and p-p38MAPK was increased in NOZ cells after treatment
with TNF-α. i-k The effect of inhibition of MAPK pathway members on the promoter activity and protein expression of CCR7. When treated with
PD98059 (50 μM), SP600125 (10 μM) or SB203580 (20 μM), the expression of AP-1 and p-AP-1 in NOZ cells was reduced. However, the promoter
activity and protein expression of CCR7 were significantly reduced only in the PD98059- and SP600125-treated groups (*P < 0.05). All of the
experiments were repeated three times
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SP600125 (10 μM) or SB203580 (20 μM) resulted in re-
duced expression of AP-1 and p-AP-1. However, the
promoter activity and protein expression of CCR7 were
significantly reduced in the PD98059- and SP600125-
treated groups (compared to control and the TNF-α-
treated groups, P < 0.05) but not in the SB203580-
treated group. Therefore, ERK1/2 and JNK are involved
in the TNF-α/AP-1/CCR7 signalling pathway.
Taken together, these results indicated that TNF-α
promotes AP-1 binding to the CCR7 promoter and
upregulates CCR7 expression through the “ERK1/2-
AP-1 and JNK-AP-1” pathways.
5. Knock-down of CCR7 expression in NOZ cells
using RNAi.
To find an effective siRNA to silence CCR7
expression, we designed three siRNA target
sequences (si1, si2 and si3) from the human CCR7
gene (GenBank accession NO. NM_001301714.1)
and a non-targeting control (siNC) (Fig. 4a). CCR7
protein in NOZ cells transiently transfected with
siRNA oligos was detected by Western blotting. The
results showed that the si3 oligos effectively knocked
down the expression of CCR7 in NOZ cells
compared to the negative control and siNC groups
(Fig. 4b, c). Next, we used a lentiviral vector
expressing the si3/shRNA construct (named
LV-shCCR7) and a control vector containing a
non-targeting sequence (named LV-shNC) to establish
stably expressing cell lines. As shown in Fig. 4d, e, the
protein level of CCR7 in the LV-shCCR7 group (NOZ
cells stably infected with lentiviral CCR7 shRNA)
was significantly decreased relative to the NOZ or
LV-shNC (NOZ cells infected with empty vector)
group (*P < 0.05). These cells were then used for the
following cell and animal experiments.
6. TNF-α promotes GBC cells migrating to LECs
through upregulation of CCR7.
To determine the role of CCR7 in the directional
migration of GBC cells to LECs and whether TNF-α
enhanced this migration and invasiveness, a
transwell assay was performed. Following staining
with H&E, 5 different fields (×400, magnification)
were counted to determine the numbers of migrated
and invaded cells. Figure 5a, b shows that the total
number of cells in the NOZ + LEC group that
migrated and invaded through the transwell
polycarbonate filter was significantly higher than
that of the cells in the NOZ group (P < 0.05),
suggesting that NOZ cells directionally migrated to
HDLECs. It was demonstrated that TNF-α
dramatically enhanced the migratory ability of NOZ
cells to HDLECs (Fig. 5b, c, NOZ + LEC + TNF
group vs NOZ + LEC group, P < 0.05), and this effect
was impaired when the CCR7 was knocked down by
Fig. 4 Expression of CCR7 in NOZ cells using RNAi technology. a Three siRNA oligos targeting the CCR7 gene (si1, si2 and si3) and a non-targeting
control (siNC) were designed and chemically synthesized, and then transiently transfected into the NOZ cells. b, c The CCR7 protein in NOZ cells
transfected with siRNA oligos was detected by Western blotting. The relative expression of CCR7 in the cells transfected with si3 oligos was significantly
reduced compared to the negative control and siNC groups (*P < 0.05). d Construction of a NOZ cell line stably expressing lentiviral CCR7 (producing
si3 sequence) or NC shRNA and a green fluorescent protein sequence. The cells were observed under a fluorescence microscope with blue light. e
The CCR7 expression of NOZ cells stably transfected with LV-shCCR7 and LV-shNC was analyzed by western blotting. The protein level of CCR7 in the
LV-shCCR7 group was significantly decreased relative to the LV-shNC group (*P < 0.05)
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lentiviral-mediated shRNA (Fig. 5c–e, LV-shCCR7 +
LEC + TNF group vs NOZ + LEC + TNF/LV-shNC +
LEC + TNF groups, P < 0.05).
7. TNF-α promotes lymph node metastasis through
the upregulation of CCR7 in the orthotopic
transplantation of GBC.
To observe whether TNF-α promotes lymph node
metastasis through upregulation of CCR7 in vivo, we
established two orthotropic xenograft models by
planting NOZ and LV-shCCR7 cells in the gallbladder
of nude mice (Fig. 6a). After 2 weeks, TNF-α or
normal saline was injected into the peritoneal cavity
of nude mice three times a week for three weeks.
Lymph node metastases (LNM) of GBC were ob-
served with the naked eye (Fig. 6c) and confirmed by
HE staining (Fig. 6d). As shown in Table 5, TNF-α
increased the LNM of orthotropic xenograft tumours
compared to the control group, and this effect was
impaired when the CCR7 was knocked down by
lentiviral-mediated shRNA (LV-shCCR7 group). We
also observed ascites and hepatic metastases in
some mice (Fig. 6b).
Discussion
Chemokine receptors and ligands play a critical role in
the control of directional migration of many cell types,
such as inflammatory cells [23, 24], immune cells and
lymphocytes [12, 25]. Similar to the process of inflam-
matory cell recruitment and lymphocyte homing, che-
mokine receptors and ligands play important roles in
mediating tumour cell transfer to target organs. Recently,
many studies demonstrated that chemokine receptors and
ligands are involved in tumourigenesis and tumour devel-
opment. As mentioned above, CC chemokine receptor 7
(CCR7) is associated with lymphatic metastasis in certain
types of tumours. However, the relationship between
CCR7 and the lymph node metastasis of gallbladder can-
cer has not yet been reported.
In the present study, we used immunohistochemical
techniques to investigate the expression of CCR7 in 42
gallbladder cancer specimens and 22 samples of normal
gallbladder tissues adjacent to the cancer site. The re-
sults indicated that CCR7 is overexpressed in gallbladder
cancer tissues, and is at low expression in normal tis-
sues. The correlation with clinicopathologic factors was
also analyzed. The high expression of CCR7 was signifi-
cantly correlated with the AJCC staging and lymph node
metastasis of GBC patients, which suggests that CCR7
may promote the development, especially the lymphatic
metastasis, of GBC. Moreover, CCR7 expression was
confirmed in all three GBC cell lines: NOZ, GBC-SD,
and SGC-996. Against these backgrounds, we speculated
that high expression of CCR7 may promote lymph node
metastasis in GBC.
TNF-α is the key player in cancer-related inflamma-
tion, which can promote carcinogenesis, tumour growth,
invasion, angiogenesis and epidermal-mesenchymal tran-
sition (EMT) [26–29]. However, little is known about
the relation between TNF-α and lymphatic metastasis of
the malignancies. In our previous study, we found that
TNF-α can promote lymphangiogenesis and lymph node
metastasis of GBC through upregulation of vascular
endothelial growth factor C (VEGF-C) [8]. However, fac-
tors that are involved in the spread of GBC cells to the
Fig. 5 Effect of the TNF-α-CCR7 axis on the directional migration of GBC cells. a Migratory ability of the group that contained NOZ cells in the
upper chamber only, without HDLECs in the lower chamber. b NOZ cells in the upper chamber and HDLECs in the lower chamber. c NOZ cells
treated with 20 ng/mL TNF-α in the upper chamber and HDLECs in the lower chamber. d LV-shNC cells treated with 20 ng/mL TNF-α in the
upper chamber and HDLECs in the lower chamber. e LV-shCCR7 cells treated with 20 ng/mL TNF-α in the upper chamber and HDLECs in the
lower chamber. f Numbers of migrated cells in all 5 groups (*P < 0.05)
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lymphatic system induced by TNF-α have been less well
studied. Thus, we speculated that TNF-α might promote
lymphatic metastasis of gallbladder cancer through up-
regulation of CCR7. We first analyzed the relationship
between TNF-α and CCR7 via the detection of 20
clinical samples, and found that the level of TNF-α in
the bile of GBC patients with strong CCR7 staining
was significantly higher than that of patients with
negative/week/moderate staining, which suggests that
TNF-α is positively correlated with CCR7. Next, we
employed exogenous TNF-α to stimulate the NOZ
and SGC-996 cell lines, and found that TNF-α can
significantly increase the expression of CCR7 in a
dose- and time-dependent manner. These meaningful
results prompted us to further explore the specific
molecular mechanism underlying the TNF-α induced
upregulation of CCR7.
Fig. 6 The TNF-α-CCR7 axis is involved in lymph node metastasis of GBC in vivo. a Establishment of orthotopic xenograft models of GBC in nude
mice. After anaesthesia and exposure of the gallbladder (black arrow), one of two NOZ cell lines (NOZ or LV-shCCR7) was injected into the cavity
of the gallbladder. b-c Gross anatomy of the nude mice. Ascites (green arrow) and hepatic metastasis (white arrow) were observed in the
orthotopic xenograft models (b). The metastatic lymph nodes (blue arrow) are mainly located in the hepatoduodenal ligament (c). d
Lymph node metastasis was further confirmed by H-E staining (200×). The invasive tumour cells (yellow arrow) could be observed in the
lymphoid follicles (red arrow)
Table 5 Lymph node metastasis (LNM) of the orthotopic
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TNF-α has dual effects on tumours (anti-cancer or
pro-cancer effect), which are due to the activation of dif-
ferent downstream signalling pathways followed by the
combination of TNF-α and its receptor TNFR1 [30].
According to the literature, three signalling pathways as-
sociated with TNF-α-induced tumour development are
described below: the TNF-α - TNFR1 - signalling com-
plex - MAP3K3/MEKK3/TAK1 - NF-κB pathway, the
TNF-α - TNFR1 - signalling complex - MAP3K (ASK1) -
JNK or p38 MAPK - AP-1 pathway and the TNF-α -
TNFR1 - Ras - Raf - MEK1 - ERK1/2 - AP-1 pathway
[31]. Thus, we first analyzed the activity of the CCR7
promoter (Fig. 3a) and searched for potential binding
sites of NF-κB or AP-1 in the -243 nt to -108 nt re-
gion of the CCR7 promoter by using the TFbind and
Promoter Scan programs. Two putative AP-1 binding
sites were found in this region, whereas NF-κB sites
were not identified (Fig. 3b). Site-directed mutagenesis
and ChIP assays were then used to reveal that the
AP-1(2) site is crucial for the activity of CCR7 pro-
moter but not the AP-1(1) binding site. To verify the
molecules upstream of CCR7, we used siRNA to
knock down AP-1. The promoter activity and the
protein level of CCR7 were consequently decreased in
both groups, with or without TNF-α treatment. Sub-
sequently, we analyzed the effect of inhibition of
MAPK pathway members on the promoter activity
and protein expression of CCR7. The results sug-
gested that ERK1/2 and JNK are upstream of AP-1.
These data confirm the existence of the “TNF-α -
ERK1/2 - AP-1 - CCR7” and “TNF-α - JNK - AP-1 -
CCR7” pathways in NOZ cells. Mburu YK et al.
reported that NF-κB and AP-1 co-regulate CCR7 ex-
pression in metastatic squamous cell carcinoma of the
head and neck [32]. The AP-1 site they found is con-
sistent with our data. In another study, Côté SC et al.
found that the transcription factors CREB-1, C/EBPα
and C/EBPβ can bind the CCR7 promoter region in
human monocytes [33]. These studies showed that
multiple transcription factors are involved in the
regulation of CCR7 expression, while the specific
mechanism may differ in different cell types.
Next, we wanted to determine the role of the TNF-α -
CCR7 axis in the migration of GBC cells to the lymph-
atic system. We first successfully established a NOZ cell
line stably expressing lentiviral CCR7 shRNA which ef-
fectively silenced the expression of CCR7 (Fig. 4). Next,
a transwell assay was performed. We seeded NOZ cells
in the upper chamber of the transwell system and
HDLECs in the lower chamber. The results indicated
that NOZ cells directionally migrated to HDLECs, and
TNF-α dramatically enhanced this migration. This en-
hancement induced by TNF-α was impaired when CCR7
was knocked down by lentiviral-mediated shRNA (Fig. 5).
It was demonstrated that the lymphatic endothelial cells
(LECs) secreted the chemokines CCL21 and CCL19,
which are not secreted by blood endothelial cells (BECs)
[34]. CCL21 and CCL19 are specific ligands for CCR7.
Together with our data, we consider that the combin-
ation of CCL21/CCL19 (secreted by LECs) and CCR7
(located on the GBC cell membrane) prompts GBC cells
to directionally migrate to the lymphatic vessels, eventu-
ally leading to lymph node metastasis.
To confirm our above conclusion in vivo, we con-
ducted animal experiments. The results indicated that
TNF-α can increase the lymph node metastasis of ortho-
topic xenograft tumours in nude mice, and this effect
was impaired when CCR7 was silenced. These data dem-
onstrate that CCR7 can mediate the TNF-α-induced
lymphatic metastasis of gallbladder cancer in vivo. Con-
sistent with our results, previous reports support the
conclusion that CCR7 could promote lymph node me-
tastasis. Emmett MS et al. observed that CCR7 mediates
directed growth of melanomas towards lymphatics; they
called this process in-transit metastasis [17]. Heather D.
Cunningham et al. indicated that CCR7 mediates metas-
tasis of breast cancer to the lymph nodes in mice [35].
Conclusions
Our study suggests that CCR7 is highly expressed in
GBC, and it mediates the TNF-α-induced lymphatic me-
tastasis of GBC through the “ERK1/2 - AP-1 - CCR7”
and “JNK - AP-1 - CCR7” pathways. These data indicate
that CCR7 may be used as a potential treatment target
in preventing lymphatic metastasis of gallbladder cancer.
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